K&M Position Statement: Semaglutide for Reducing the Risk of Major Adverse Cardiovascular Events in People with Cardiovascular Disease and Overweight or Obesity

On Formulary Preferred
On Formulary Second Line
On Formulary Third Line

Specialist Initiation
Secondary Care Only
Not Approved for Formulary